8 years of historical data (2018–2025) · Healthcare · Medical - Devices
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
LENSAR, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $63M | $139M | $103M | $39M | $30M | $56M | $79M | — | — |
| Enterprise Value | $53M | $129M | $89M | $20M | $18M | $28M | $42M | — | — |
| P/E Ratio → | -1.82 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.08 | 2.38 | 1.92 | 0.91 | 0.85 | 1.63 | 3.00 | — | — |
| P/B Ratio | — | — | 5.52 | 0.82 | 0.72 | 1.02 | 1.18 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.20 | 1.67 | 0.48 | 0.51 | 0.81 | 1.61 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
LENSAR, Inc. earns an operating margin of -42.1%. Operating margins have compressed from -29.0% to -42.1% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.4% | 46.4% | 48.3% | 50.1% | 56.4% | 51.8% | 53.4% | 43.3% | 39.4% |
| Operating Margin | -42.1% | -42.1% | -19.9% | -29.0% | -57.1% | -57.0% | -70.1% | -41.6% | -38.2% |
| Net Profit Margin | -58.7% | -58.7% | -58.7% | -34.1% | -56.3% | -56.9% | -75.0% | -48.0% | -51.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -95.4% | -32.3% | -41.1% | -32.1% | -107.9% | — | — |
| ROA | -49.8% | -49.8% | -46.2% | -22.9% | -32.6% | -26.9% | -34.8% | -46.2% | -43.6% |
| ROIC | — | — | -47.2% | -31.1% | -53.4% | -51.7% | -175.8% | -689.2% | -40.2% |
| ROCE | -59.8% | -59.8% | -19.5% | -23.9% | -39.5% | -30.6% | -38.0% | -53.1% | -43.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $13M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.14 | 0.05 | 0.07 | 0.06 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.73 | -0.39 | -0.28 | -0.52 | -0.55 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -13.76 | -6.32 | — |
Net cash position: cash ($13M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.15x means LENSAR, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.62x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.99x to 1.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.15 | 1.15 | 2.80 | 3.99 | 2.95 | 5.14 | 6.90 | 2.19 | 1.53 |
| Quick Ratio | 0.62 | 0.62 | 2.04 | 2.64 | 1.92 | 4.40 | 5.30 | 1.16 | 1.00 |
| Cash Ratio | 0.44 | 0.44 | 1.50 | 2.07 | 1.28 | 3.63 | 4.79 | 0.59 | 0.44 |
| Asset Turnover | — | 0.82 | 0.81 | 0.61 | 0.63 | 0.52 | 0.33 | 0.88 | 0.84 |
| Inventory Turnover | 1.46 | 1.46 | 2.42 | 1.34 | 1.31 | 2.56 | 0.91 | 2.15 | 3.64 |
| Days Sales Outstanding | — | 39.83 | 44.21 | 37.43 | 64.42 | 52.83 | 33.98 | 46.46 | 49.42 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
LENSAR, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 2.3% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | — | — |
| Shares Outstanding | — | $12M | $12M | $11M | $10M | $9M | $11M | $11M | $1M |
Compare LNSR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $63M | -1.8 | — | — | 46.4% | -42.1% | — | — | — | |
| $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — | |
| $12B | 29.8 | 13.9 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 | |
| $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 | |
| $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 | |
| $2B | 978.1 | 23.6 | 22.7 | 42.5% | 0.4% | 0.2% | 0.3% | 2.4 | |
| $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 | |
| $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 | |
| $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 | |
| $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 | |
| $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 | |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonQuick answers to the most common questions about buying LNSR stock.
LENSAR, Inc.'s current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
Based on historical data, LENSAR, Inc. is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
LENSAR, Inc. has 46.4% gross margin and -42.1% operating margin.